Hikma PharmaceuticalsHKMPF +4.28%82 OCF Yield % is 10.13 as of Jul. 01, 2026, which is 9% above its 10-year median of 9.28. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $27.88 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,004 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 78.98% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Hikma Pharmaceuticals OCF Yield % Related Terms
Hikma Pharmaceuticals OCF Yield % Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPF) has a OCF Yield % of 10.13 as of Jul. 01, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Hikma Pharmaceuticals and its competitors. This is near median its historical median of 9.28. Over the past decade, Hikma Pharmaceuticals' OCF Yield % has ranged from 4.62 to 17.20. According to the industry distribution chart, Hikma Pharmaceuticals ranks #211 out of 1004 companies in the Drug Manufacturers industry, placing it in the top 21%.
Is Hikma Pharmaceuticals' OCF Yield % too high?
Hikma Pharmaceuticals' current OCF Yield % of 10.13 is near median its 10-year median of 9.28. Over the past 10 years, this metric has ranged from a low of 4.62 to a high of 17.20. The Drug Manufacturers industry median OCF Yield % is 3.50. Hikma Pharmaceuticals' value of 10.13 is 189.8% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #211 out of 1004 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #211 out of 1004 companies for OCF Yield %. This places Hikma Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 3.50. Hikma Pharmaceuticals' value of 10.13 is 189.8% above this benchmark. Historically, Hikma Pharmaceuticals' own OCF Yield % has ranged from 4.62 to 17.20 over the past decade. While the company's 10-year median is 9.28 vs. the industry median of 3.50, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.50, based on 1,004 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current OCF Yield % of 10.13 is 189.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current OCF Yield % is 10.13, which is near median its own 10-year median of 9.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.88, compared to a current price of $20.12 — trading 27.9% below its estimated fair value. The current OCF Yield % is 10.13, which is near median its 10-year median of 9.28 and 189.8% above the Drug Manufacturers industry median of 3.50. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current OCF Yield % is 10.13 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.12 is trading 27.9% below its estimated GF Value™ of $27.88.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
OCF Yield %: 10.13 (near median its 10-year median of 9.28)
GF Value™: $27.88 vs. price of $20.12 (27.9% below fair value)
Industry Position: 189.8% above the Drug Manufacturers median (#211 of 1004)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
